Lung cancer is the leading cause of cancer death worldwide. A major goal in this field is to identify novel targets to treat tumors. Some reports indicated that transmembrane protein CD22 was expressed on lung cancer cells and might serve as a new target for therapy. In the present study, the researchers used a combination of flow cytometry and Western blot analyses with a variety of CD22 monoclonal antibodies and could not detect surface or intracellular expression of CD22 protein in a panel of human lung cancer cell lines. In addition, the proliferation of these cancer cell lines in vitro was not affected using CD22 antibodies or a highly potent anti-CD22 immunotoxin. The study concludes by asking for more investigation on the reality of CD22 as a specific marker of cancer cells before any development of therapy is made.
A reevaluation of CD22 expression in human lung cancer
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!